Education
About Us
Working with TipRanks
Follow Us
Inovio Pharmaceuticals (INO)
NASDAQ:INO
INO Stock Chart & Stats
$2.47
-$0.22(-9.65%)
At close: 4:00 PM EST
$2.47
-$0.22(-9.65%)
Day’s Range― - ―
52-Week Range$1.30 - $5.83
Previous CloseN/A
Volume1.36M
Average Volume (3M)1.15M
Market Cap
$124.89M
Enterprise Value$42.13M
Total Cash (Recent Filing)$47.55M
Total Debt (Recent Filing)$10.66M
Price to Earnings (P/E)―
Beta1.52
Next Earnings
Nov 11, 2025EPS Estimate
-0.42Last Dividend Ex-Date
Sep 28, 2017Dividend YieldN/A
Share Statistics
EPS (TTM)-0.61
Shares Outstanding53,142,662
10 Day Avg. Volume1,032,805
30 Day Avg. Volume1,146,585
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.34
Enterprise Value/Revenue231.04
Enterprise Value/Gross Profit-20.05
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$6.96Price Target Upside181.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyINO-3107 provided significant clinical benefit to RRP patients, as measured by reduction in surgery, which continued to improve in years two and three following initial treatment.
Regulatory ProgressThe company is on track to submit the Biologics License Application (BLA) for INO-3107, with the goal of having FDA acceptance of the submission by the end of 2025.
Bears Say
Capital RequirementsThe company may need to raise additional capital within the next 12 months.
Regulatory Approval RisksINO-3107 may not gain regulatory approval in RRP or meet sales forecasts.
Inovio Pharmaceuticals News
INO FAQ
What was Inovio Pharmaceuticals’s price range in the past 12 months?
Inovio Pharmaceuticals lowest stock price was $1.30 and its highest was $5.83 in the past 12 months.
What is Inovio Pharmaceuticals’s market cap?
Inovio Pharmaceuticals’s market cap is $124.89M.
When is Inovio Pharmaceuticals’s upcoming earnings report date?
Inovio Pharmaceuticals’s upcoming earnings report date is Nov 11, 2025 which is in 20 days.
How were Inovio Pharmaceuticals’s earnings last quarter?
Inovio Pharmaceuticals released its earnings results on Aug 12, 2025. The company reported -$0.61 earnings per share for the quarter, the consensus estimate of -$0.61 by $0.
Is Inovio Pharmaceuticals overvalued?
According to Wall Street analysts Inovio Pharmaceuticals’s price is currently Undervalued.
Does Inovio Pharmaceuticals pay dividends?
Inovio Pharmaceuticals pays a Monthly dividend of $0.069 which represents an annual dividend yield of N/A. See more information on Inovio Pharmaceuticals dividends here
What is Inovio Pharmaceuticals’s EPS estimate?
Inovio Pharmaceuticals’s EPS estimate is -0.42.
How many shares outstanding does Inovio Pharmaceuticals have?
Inovio Pharmaceuticals has 53,142,662 shares outstanding.
What happened to Inovio Pharmaceuticals’s price movement after its last earnings report?
Inovio Pharmaceuticals reported an EPS of -$0.61 in its last earnings report, expectations of -$0.61. Following the earnings report the stock price went up 14.094%.
Which hedge fund is a major shareholder of Inovio Pharmaceuticals?
Currently, no hedge funds are holding shares in INO
Inovio Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.96 (181.78% Upside)
$6.96 (181.78% Upside)
Blogger Sentiment
Bullish
INO Sentiment 100%
Sector Average 69%
Sector Average 69%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 1.6%
Last 30 Days ▼ 1.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-58.55%
12-Months-Change
Fundamentals
Return on Equity
-140.12%
Trailing 12-Months
Asset Growth
-49.00%
Trailing 12-Months
Company Description
Inovio Pharmaceuticals
Inovio Pharmaceuticals (INO) is a biotechnology company focused on developing innovative DNA-based immunotherapies and vaccines for the treatment of cancer and infectious diseases. The company specializes in its proprietary platform technology that delivers therapeutic DNA plasmids into the body, harnessing the immune system to generate a targeted response. Inovio's core products include its investigational therapies for various cancers and its work on vaccines against infectious diseases, including COVID-19.
INO Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress with the BLA submission for INO-3107, successful FDA inspections, and advancements in DNA medicine technology, suggesting a promising outlook. However, concerns over decreased cash reserves and potential competition were noted.View all INO earnings summariesINO Stock 12 Month Forecast
Average Price Target
$6.96
▲(181.78% Upside)
Technical Analysis
Agenus
―
Oncolytics Biotech
―
Oncolytics Biotech
―
Atossa Therapeutics
―
Anixa Biosciences
―
Instil Bio
―
Ownership Overview
0.54% Insiders
4.85% Mutual Funds
0.09% Other Institutional Investors
90.64% Public Companies and
Individual Investors